Background and objective: Drug-resistant pathogen (DRP) risk stratification is important for choosing a treatment strategy for community-onset pneumonia. Evidence for benefits of non-antipseudomonal β-lactam plus macrolide combination therapy (BLM) on mortality is limited in patients at low DRP risk. Risk factors for mortality remain to be clarified. Methods: Post hoc analysis using a prospective multicentre study cohort of community-onset pneumonia was performed to assess 30-day differences in mortality between non-antipseudomonal β-lactam monotherapy (BL) and BLM groups. Logistic regression analysis was performed to assess the therapeutic effect and risk factors for mortality in patients at low DRP risk. Results: In total, 594 patients with community-onset pneumonia at low DRP risk (369 BL and 225 BLM) were analysed. The 30-day mortality in BL and BLM was 13.8% and 1.8%, respectively (P < 0.001). Multivariate analysis showed that BLM reduced the 30-day mortality (adjusted odds ratio: 0.28, 95% CI: 0.09-0.87) compared with BL. Independent prognostic factors for 30-day mortality included arterial partial pressure of carbon dioxide (PaCO 2 ) > 50 mm Hg, white blood cell count < 4000/mm 3 , non-ambulatory status, albumin < 3.0 g/dL, haematocrit < 30%, age ≥ 80 years, respiratory rate > 25/min and body temperature < 36 C. Conclusion: In patients with community-onset pneumonia at low DRP risk, BLM treatment reduced 30-day mortality compared with BL. Independent risk factors for mortality are potential confounding factors when assessing antibiotic effects in randomized clinical trials.
INTRODUCTION
Pneumonia is a common and life-threatening disease. 1 Effective initial antibiotic treatment for patients with pneumonia is an ongoing challenge. [2] [3] [4] [5] [6] Our previous study demonstrated that treatment strategies of community-acquired pneumonia (CAP) and healthcareassociated pneumonia (HCAP) could be unified because risk factors for drug-resistant pathogens (DRPs) were identical between patients with CAP and HCAP. 7 Therefore, the two pneumonia categories have been combined into the single category of community-onset pneumonia. [8] [9] [10] Stratification of the risk for DRPs is critical in determining initial antibiotics for patients with community-onset pneumonia. 7, [9] [10] [11] The role of combination therapy with a macrolide has been evaluated in several studies including patients with CAP. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Previous studies report that mortality was lower in patients with severe CAP who received non-antipseudomonal β-lactam plus macrolide combination therapy (BLM) than in those who received other regimens such as nonantipseudomonal β-lactam monotherapy (BL). 4, 5, [15] [16] [17] [18] [19] 23 For patients with mild-to-moderate CAP, a recent randomized controlled trial showed no difference in the mortality among BLM, BL and fluoroquinolone monotherapy groups. 22 On the other hand, another randomized controlled trial demonstrated that a proportion of patients reached clinical stability and that of the 30-day readmission was lower in the BLM group than in the BL group. 21 Therefore, the best antibiotic treatment strategy is still unclear. Regarding initial antibiotic selection based on the risk for DRPs, few studies have shown further benefits of macrolides in addition to β-lactams in patients with communityonset pneumonia at low risk for DRPs. In addition, confounding factors for outcomes among those patients are unclear when antibiotic treatment effects are assessed appropriately.
In this study, we performed a post hoc analysis using a multicentre prospective observational study cohort of community-onset pneumonia. 7, 24 The aims of this study were as follows: (i) to assess the potential effects of adding a macrolide to non-antipseudomonal β-lactams in patients with community-onset pneumonia at low risk for DRPs and (ii) to determine the risk factors for mortality that should be considered as candidate confounding factors in future clinical trials of antibiotic treatment for those patients.
METHODS

Study design, participants and procedures
In this study, post hoc analyses to evaluate the effects of BLM were performed using prospectively collected data of an observational study in patients with pneumonia. This study was conducted at 10 medical institutions in Japan from 15 March to 22 December 2010. 7 Briefly, hospitalized adult patients (aged ≥20 years) with community-onset pneumonia, including both CAP and HCAP, were enrolled. Patients with hospitalacquired and ventilator-associated pneumonia were excluded. Therapeutic drugs were assigned based on physicians' decision. This study was approved by the institutional review boards of the medical institutions. The protocol for this study adhered to the Japanese Ethical Guidelines for Epidemiological Studies. This study was registered with the University Medical Information Network in Japan, number UMIN000003306. Details about the definition of variables, procedures, data collection, microbacteriological evaluation and susceptibility test of antibiotics in the prospective study are described elsewhere.
7,24
Assessment of the risk for DRPs
Identified pathogens not susceptible to antibiotics commonly used for patients with CAP, including nonantipseudomonal β-lactams (ceftriaxone or ampicillin/ sulbactam), macrolides (azithromycin or clarithromycin) and fluoroquinolones (moxifloxacin, levofloxacin or garenoxacin), were defined as CAP-DRPs (e.g. Pseudomonas aeruginosa, extended spectrum β-lactamaseproducing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus (MRSA)). 7 Our previous study identified six independent risk factors for CAP-DRPs in patients with community-onset pneumonia. 7 The risk factors included use of antibiotics within the previous 90 days, hospitalization for ≥2 days during the preceding 90 days, immunosuppression, use of gastric acid suppressive agents, tube feeding and non-ambulatory status. Furthermore, we also clarified three MRSAspecific risk factors that included chronic dialysis during the preceding 30 days, positive MRSA history and congestive heart failure. According to the cumulative number of CAP-DRP risk factors, patients with community-onset pneumonia were defined as at low risk for drug resistance when they had no or one risk factor for CAP-DRPs or when they had two risk factors for CAP-DRPs and no MRSA-specific risk factors. 7 Clinical outcomes were compared in patients with community-onset pneumonia at low CAP-DRP risk between the BL and BLM groups. Patients who received other antibiotic regimens on admission were excluded from the analysis. In addition, patients who had a history of antibiotic use within 90 days prior to the admission were also excluded, because previous antibiotics included β-lactams and/or macrolides in some patients and their previous use might affect patients' outcomes in this study.
Outcomes
In this study, we assessed the 30-day all-cause mortality. Early treatment failure and length of hospital stay were also evaluated. Early treatment failure was defined in patients with the following conditions within 72 h of admission: (i) death; (ii) deterioration of respiratory condition including requirement for higher oxygen supply than at diagnosis or mechanical ventilation support; (iii) deterioration of circulation dynamics including requirement for aggressive fluid resuscitation or vasopressor support; (iv) change of therapeutic agents from initial agents to others because of clinical instability; and (v) necessity of invasive procedures for diagnostic and therapeutic purposes, including chest tube drainage or bronchoscopic examination.
Statistical analysis
All tests were two-tailed and a P-value <0.05 was considered statistically significant. Categorical data were summarized as frequencies in percentage. Pearson's chi-square test or Mantel extension test for trend was used for discrete variables analyses and Wilcoxon test for continuous variables.
To assess the combination effect of BLM on the 30-day mortality, candidate confounding factors were defined a priori based on previous reports.
2,24-30 The variables included, gender, age, co-morbidities, nonambulatory status, physical findings, laboratory findings and radiographic findings, are shown in Tables 1  and S2 (Supplementary Information) . Using these variables, univariate and multivariate logistic regression analyses were performed. A forward stepwise selection procedure was used with inclusion of variables that had P < 0.10. Adjusted odds ratios (AOR) and the corresponding 95% confidence interval (CI) were calculated.
In additional analyses, we compared the effect on the 30-day mortality between the BL and BLM groups in patients who received theoretical appropriate antibiotic treatment using monotherapy with a β-lactam (ceftriaxone or ampicillin/sulbactam), that is, in whom identified pathogens were susceptible to ceftriaxone or ampicillin/sulbactam and were not atypical pathogens.
Furthermore, in patients with community-onset pneumonia at low risk for CAP-DRPs, we investigated the combination effect of BLM on the 30-day mortality in the following patient groups: pneumonia category CAP versus HCAP; C-reactive protein (CRP) > 15 mg/ dL (high inflammatory condition) versus ≤15 mg/dL 31 ; and Pneumonia Severity Index (PSI) class I-III versus IV-V. All statistical analyses were performed using PASW Statistics 24 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient flow and baseline characteristics
In total, 1742 patients with pneumonia were assessed for eligibility. Of the 1413 patients with communityonset pneumonia (887 CAP and 526 HCAP), 1183 were at low risk for CAP-DRPs. After exclusion of 358 patients who received antibiotics prior to admission and 231 who received antibiotics other than BL and BLM, 594 patients (369 received BL and 225 received BLM) were included in the analysis (Fig. 1) . The baseline characteristic between treatment groups are shown in Table 1 . Elderly, non-ambulatory status, haematocrit < 30%, albumin level < 3.0 g/dL, arterial partial pressure of carbon dioxide (PaCO 2 ) ≥ 50 mm Hg and severe pneumonia were more frequent in the BL group than in the BLM group.
Identified pathogens
The distribution of identified pathogens at diagnosis is shown in Table S1 (Supplementary Information). Pathogens were identified in 59.6% (220/369) and 56.9% (128/225) of the BL and BLM groups, respectively. In the BL group, Streptococcus pneumoniae was most frequent, followed by Klebsiella pneumoniae and methicillin-susceptible S. aureus. Streptococcus pneumoniae was also the leading identified pathogen in the BLM group, followed by Haemophilus influenzae and K. pneumoniae. CAP-DRPs were identified in 4.9% of the BL group and 0.9% of the BLM group, respectively.
Effect of antibiotic therapy on the 30-day mortality and the risk factors Figure 2 shows crude clinical outcomes between the BL and BLM groups. The 30-day mortality proportion was lower in the BLM group than in the BL group (1.8% vs 13.8%, respectively). Compared with the BL group, the BLM showed a lower proportion of early treatment failure. The median length of hospital stay was also shorter in the BLM than that in the BL group.
To assess the effect on 30-day mortality, multivariate analysis was performed after univariate analysis for each variable (Table S2 , Supplementary Information) and the resulting adjusted effect of BLM in patients at low risk for CAP-DRPs is shown in Add-on effect of macrolides in patients with pathogens susceptible to nonantipseudomonal β-lactams
To reduce the effects of differences in pathogen distributions between the treatment groups, we performed a subgroup analysis to evaluate the treatment effect on 30-day mortality in patients with pathogens susceptible to non-antipseudomonal β-lactams (cases in which BL monotherapy is theoretically an appropriate antibiotic treatment), regardless of the risk for CAP-DRPs. Of the 1413 patients with community-onset pneumonia, 442 had identified pathogens susceptible to nonantipseudomonal β-lactams, ceftriaxone and ampicillin/sulbactam and 241 patients (149 BL and 92 BLM) were analysed (Fig. S1, Supplementary Information) . In the multivariate analysis adjusted by the eight host factors shown in Table 2 , BLM tended to reduce the 30-day mortality compared with BL (AOR: 0.33, 95% CI: 0.06-1.86) ( Table 3) .
Subgroup analyses according to pneumonia category, CRP level and severity in patients at low risk for CAP-DRPs
The BLM group was more likely than the BL group to tend to reduce 30-day mortality in patients with HCAP at low risk for CAP-DRPs as well as those with CAP (AOR (95% CI): 0.28 (0.03-2.66) vs 0.33 (0.08-1.27), respectively) (Table 3) . Similarly, BLM had a tendency to reduce 30-day mortality in community-onset pneumonia patients with both CRP levels of <15 and ≥15 mg/dL (AOR (95% CI): 0.30 (0.08-1.10) vs 0.33 (0.04-3.01), respectively). The trend for mortality reduction by BLM was more obvious in patients with severe pneumonia (PSI class ≥ IV) (AOR (95% CI): 0.33 (0.10-1.02)) compared to those with non-severe pneumonia.
DISCUSSION
In this post hoc analysis using data from the multicentre prospective observational study cohort of patients with community-onset pneumonia, the results suggest that BLM may improve the 30-day survival in patients at low risk for CAP-DRPs. In those patients, we defined eight independent risk factors for the 30-day mortality, including hypercapnia, leucopenia, non-ambulatory status, low albumin level, low haematocrit, older age, tachypnoea and low body temperature. These host factors should be considered as candidate confounding factors to assess antibiotic treatment efficacy in patients with communityonset pneumonia at low risk for CAP-DRPs.
The 2016 Infectious Diseases Society of America/ American Thoracic Society guidelines for hospitalacquired and ventilator-associated pneumonia state that the treatment strategy for patients with communityonset pneumonia including both CAP and HCAP should be determined based on the risk for DRPs. 32 Many 34 However, to the best of our knowledge, there are few studies to investigate the effect in those patients. Therefore, our present study provides insights on BLM effects on mortality of patients with community-onset pneumonia at low risk for CAP-DRPs.
Compared with BL, BLM reduced the 30-day mortality in the low CAP-DRP risk group with an OR of 0.28 after adjustment for other factors associated with mortality. In addition, we clarified independent prognostic host factors associated with 30-day mortality at diagnosis of pneumonia. For future clinical trials in patients with community-onset pneumonia at low risk for CAPDRPs, these factors should be taken into account as possible stratification factors or variables for adjustment to appropriately assess antibiotic effects on the 30-day mortality.
Subgroup analyses to compare the effect on 30-day mortality between BL and BLM revealed additional findings (Table 3) . First, we assessed the add-on effect of macrolides to β-lactams among patients in whom BL was determined to be the appropriate antibiotic treatment. BLM had a tendency to reduce the 30-day mortality in these patients compared with BL. This result suggests that macrolide effects other than appropriateness of antibiotics might affect mortality. 19 Second, although BLM efficacy was questionable in patients with HCAP, [35] [36] [37] our results suggest that BLM may be effective in patients at low risk for CAP-DRPs in HCAP as well as those in CAP. This is additional evidence in favour of unified antibiotic selection in both CAP and HCAP. Third, the trend to reduce 30-day mortality by BLM is shown in patients with either high or low CRP Tables 1 and S2 (Supplementary Information) .
BL, non-antipseudomonal β-lactam monotherapy; BLM, non-antipseudomonal β-lactam plus macrolide combination therapy; CAP-DRP, community-acquired pneumonia drug-resistant pathogen; PaCO 2 , arterial partial pressure of carbon dioxide; ref, reference. levels. Previous studies have shown that macrolides have anti-inflammatory effects. 38, 39 However, our results imply that macrolide effects are not limited to patients with hyper-inflammatory status. Finally, the mortality reduction because of BLM tended to be more evident in patients with severe pneumonia versus nonsevere pneumonia, as reported previously. 4, 5, 40 This finding is compatible with results of the study by Postma et al. in which BL was non-inferior to BLM and fluoroquinolone monotherapy in patients with CAP admitted to non-intensive care unit (ICU) wards. 22 Therefore, in community-onset pneumonia patients at low risk for CAP-DRPs, the antibiotic regimen with a non-antipseudomonal β-lactam plus a macrolide would be recommended more strongly for patients with severe pneumonia. 41 Furthermore, when planning superiority trials of antibiotics in patients with community-onset pneumonia at low risk for CAPDRPs, the criteria for enrolment should include not only patients with non-severe pneumonia but also those with severe pneumonia.
This study has several limitations. First, this study is a post hoc analysis of a prospective observational study and potential bias could not be eliminated by adjustment with multivariate logistic regression analysis. Therefore, prospective validation studies are warranted to assess the effect between BL and BLM. Second, because of insufficient number of patients, we could not compare clinical effects among three treatment groups including BL, BLM and respiratory quinolone monotherapy, and could not assess the additional effects of macrolides to broad-spectrum antibiotics in patients at high risk for CAP-DRPs. Despite these limitations, our results including the candidate confounding factors for antibiotic therapy provide useful and suggestive information for future clinical trials in patients with community-onset pneumonia.
In summary, BLM may reduce the 30-day mortality in patients with community-onset pneumonia at low risk for CAP-DRPs compared with BL. This result represents supportive data for recommending BLM in current treatment algorithm of community-onset pneumonia. Furthermore, in patients at low risk for CAP-DRPs, independent host factors associated with mortality included high PaCO 2 level, leucopenia, nonambulatory status, low serum albumin level, low , non-ambulatory status, albumin < 3.0 g/dL, haematocrit < 30%, age ≥ 80 years, respiratory rate ≥ 25/min and body temperature < 36 C. ‡ Subgroup of patients with pathogens susceptible to non-antipseudomonal β-lactams from 1413 patients with CAP and HCAP (Fig.  S1, Supplementary Information) .
§ Subgroup of the PSI score was obtained in 572 patients from 594 patients at low risk for CAP-DRPs. BL, non-antipseudomonal β-lactam monotherapy; BLM, non-antipseudomonal β-lactam plus macrolide combination therapy; CAP, community-acquired pneumonia; CAP-DRP, CAP drug-resistant pathogen; CRP, C-reactive protein; HCAP, healthcare-associated pneumonia; PaCO 2 , arterial partial pressure of carbon dioxide; PSI, Pneumonia Severity Index; ref, reference.
haematocrit, older age, tachypnoea and low body temperature. These are candidate factors for stratification to assess antibiotic effects in future clinical trials in patients with community-onset pneumonia at low CAP-DRP risk.
